Photo of Biohaven Pharmaceuticals Ringing the Opening Bell Available on Business Wire's Website and the Associated Press Photo Network

June 8, 2021 16:35 UTC

--(BUSINESS WIRE)-- A photo is available on Business Wire's website and the Associated Press Photo Network of Biohaven Pharmaceuticals (NYSE: BHVN) ringing the opening bell, June 8, 2021. BJ Jones, Chief Commercial Officer, Migraine & Common Disease and Vlad Coric, M.D., Chief Executive Officer of Biohaven ring the opening bell at the New York Stock Exchange in support of the migraine community and Migraine and Headache Awareness Month and to celebrate the FDA approval of the first and only medicine to treat and prevent migraine.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210608005948/en/

BJ Jones, Chief Commercial Officer, Migraine & Common Disease and Vlad Coric, M.D., Chief Executive Officer of Biohaven ring the opening bell at the New York Stock Exchange in support of the migraine community and Migraine and Headache Awareness Month and to celebrate the FDA approval of the first and only medicine to treat and prevent migraine. (Photo: NYSE)

BJ Jones, Chief Commercial Officer, Migraine & Common Disease and Vlad Coric, M.D., Chief Executive Officer of Biohaven ring the opening bell at the New York Stock Exchange in support of the migraine community and Migraine and Headache Awareness Month and to celebrate the FDA approval of the first and only medicine to treat and prevent migraine. (Photo: NYSE)

View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005948/en/

Contacts

Mike Beyer
Sam Brown Inc.
312-961-2502
mikebeyer@sambrown.com

Source: Biohaven Pharmaceuticals

Smart Multimedia Gallery

BJ Jones, Chief Commercial Officer, Migraine & Common Disease and Vlad Coric, M.D., Chief Executive Officer of Biohaven ring the opening bell at the New York Stock Exchange in support of the migraine community and Migraine and Headache Awareness Month and to celebrate the FDA approval of the first and only medicine to treat and prevent migraine. (Photo: NYSE)

Powered by Business Wire

View this news release and multimedia online at:
http://www.businesswire.com/news/home/20210608005948/en

Back to news